1. Home
  2. DG vs INSM Comparison

DG vs INSM Comparison

Compare DG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar General Corporation

DG

Dollar General Corporation

HOLD

Current Price

$130.97

Market Cap

27.2B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

N/A

Current Price

$125.31

Market Cap

22.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DG
INSM
Founded
1939
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2B
22.4B
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
DG
INSM
Price
$130.97
$125.31
Analyst Decision
Buy
Strong Buy
Analyst Count
21
24
Target Price
$139.60
$201.17
AVG Volume (30 Days)
2.0M
2.6M
Earning Date
06-02-2026
05-07-2026
Dividend Yield
2.07%
N/A
EPS Growth
34.05
N/A
EPS
4.49
N/A
Revenue
$42,724,369,000.00
N/A
Revenue This Year
$7.14
$182.31
Revenue Next Year
$4.17
$65.19
P/E Ratio
$29.16
N/A
Revenue Growth
5.20
N/A
52 Week Low
$95.11
$90.39
52 Week High
$158.23
$212.75

Technical Indicators

Market Signals
Indicator
DG
INSM
Relative Strength Index (RSI) 62.88 56.41
Support Level $115.31 $122.21
Resistance Level $132.31 $137.70
Average True Range (ATR) 3.86 3.90
MACD 0.85 -0.74
Stochastic Oscillator 83.84 59.50

Price Performance

Historical Comparison
DG
INSM

About DG Dollar General Corporation

Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: